Investigating the Minimum Number of Needling Required to Optimize Trigger Point Injections Outcome

NCT04732507 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Myofascial Pain
Myofascial Trigger Point Pain

Interventions

COMBINATION_PRODUCT: 1% plain lidocaine and 0.25% plain bupivacaine

Sponsor

University of Arizona